LifeMD Performance degli utili passati
Criteri Il passato verificati 0/6
LifeMD ha registrato una crescita degli utili a un tasso medio annuo di 34.6%, mentre il settore Healthcare Services ha registrato utili in crescita a un tasso medio annuo di 19.5%. I ricavi sono stati in crescita a un tasso medio annuo di 26.7%.
Informazioni chiave
34.64%
Tasso di crescita degli utili
50.26%
Tasso di crescita dell'EPS
| Healthcare Services Crescita del settore | 1.72% |
| Tasso di crescita dei ricavi | 26.75% |
| Rendimento del capitale proprio | -44.19% |
| Margine netto | -7.53% |
| Prossimo aggiornamento sugli utili | 06 May 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
LFMD: GLP-1 Virtual Care And Retention Trends Will Drive 2026 Outlook
Analysts have nudged their average price target for LifeMD slightly higher to about $9.88, citing stronger 2026 outlooks, recent Q4 beats, and growing conviction in the company's GLP-1 driven virtual care expansion and user retention trends. Analyst Commentary Recent Street research has centered on LifeMD's updated 2026 outlook, its GLP-1 focused virtual care offering, and the impact of Q4 results on the valuation debate.LFMD: GLP-1 Weight Management And Retention Trends Will Shape 2026 Outlook
Analysts maintained their average price target for LifeMD at $9.88 per share, unchanged from the previous level, as recent research points to better supported long term forecasts tied to GLP-1 driven growth expectations, updated 2026 outlooks, and stronger user retention metrics. Analyst Commentary Recent research on LifeMD centers on how well the company can execute on its GLP-1 focused growth plans, translate user retention into sustained revenue, and deliver on its 2026 outlook while keeping valuation in line with execution risk.
LFMD: GLP 1 Virtual Care Expansion Will Drive Telehealth Reacceleration
Analysts have trimmed the fair value estimate for LifeMD slightly to $14.17 from $14.22, as updated assumptions around higher expected revenue growth, improved profit margins, and a lower future P/E multiple are weighed against recent price target increases tied to stronger 2026 outlooks and GLP-1 driven virtual care expansion. Analyst Commentary Recent Street research has turned more constructive on LifeMD, with several bullish analysts revisiting their models and price targets following the latest quarterly update and 2026 outlook.LFMD: GLP-1 Focused Virtual Care Expansion Will Drive Future Weight Management Upside
The analyst price target for LifeMD has been raised from $9.25 to $9.88. Analysts attribute this to updated expectations for revenue growth, higher profit margins, and a lower assumed future P/E multiple, supported by recent research highlighting a stronger 2026 outlook, Q4 beats, and GLP-1 driven virtual care expansion.LFMD: Expanded GLP-1 Telehealth Access Will Support Future Weight Management Upside
The latest analyst price target for LifeMD now stands at $9.25, with analysts linking this valuation to updated assumptions around discount rates, profit margins, and future P/E levels. What's in the News LifeMD is now offering Novo Nordisk's Wegovy pill, described as the first and only FDA approved oral GLP-1 therapy for chronic weight management and cardiovascular health, through its telehealth platform (Key Developments).LifeMD: Still My Favorite Bargain On The Market
Feb 26LFMD: Expanded GLP-1 Telehealth Offering Will Support Future Weight Management Upside
Analysts have modestly adjusted their price target for LifeMD to $9.25, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations, while keeping their overall fair value view steady. What's in the News LifeMD is now offering Novo Nordisk's Wegovy pill, described as the first and only FDA approved oral GLP-1 therapy for chronic weight management and cardiovascular health, through its telehealth platform, expanding its branded obesity treatment options (Key Developments).Why Investors Shouldn't Be Surprised By LifeMD, Inc.'s (NASDAQ:LFMD) 31% Share Price Plunge
Feb 12
LFMD: Weight Management Headwinds Will Set Up Telehealth Reacceleration
Analysts have trimmed their implied fair value on LifeMD from about US$18.00 to roughly US$14.22 per share after cutting price targets to US$6 to US$10. They cited a higher discount rate, softer revenue and margin assumptions, and a much higher future P/E multiple tied to increased uncertainty following recent Q3 misses and competitive pressure in weight management.LFMD: Pure Play Telehealth Platform Will Benefit From Easing Weight Management Headwinds
Analysts have reduced their LifeMD price targets by about US$4 to US$8 per share overall, citing Q3 revenue and EBITDA misses, competitive pressure in virtual weight management, and updated guidance for the standalone telehealth and pharmacy business. Analyst Commentary Analysts are largely aligned on the key pressure points for LifeMD, but they differ in how they think those issues affect the company’s long term opportunity and valuation.LFMD: Telehealth Platform And Weight Management Headwinds Will Set Up Future Margin Expansion
Narrative Update on LifeMD Analysts have reset LifeMD's blended price target lower to around US$9, reflecting reduced targets ranging from US$6 to US$10 after Q3 top and bottom line misses and increased competitive pressure in weight management, while still recognizing the company as a focused telehealth and pharmacy platform with updated 2025 revenue guidance. Analyst Commentary Recent research updates on LifeMD reflect a mixed view, with analysts cutting price targets after Q3 revenue and EBITDA misses and increased competitive pressure in weight management, while still highlighting areas of execution progress and a more focused business model.LFMD: Telehealth Focus And Weight Management Reset Will Drive Future Margin Expansion
Analysts have trimmed LifeMD's average price target by several dollars per share, citing Q3 revenue and EBITDA misses, increased competitive pressure in weight management, and revised revenue guidance that temper near term expectations despite a still constructive long term outlook. Analyst Commentary Bullish analysts acknowledge the near term disappointment but stress that the core telehealth and pharmacy platform remains intact, with structural drivers that can support renewed growth once competitive and reimbursement dynamics in weight management stabilize.LFMD: Weight Management Headwinds Will Set Up Margin Expansion And Rebound Potential
Analysts have trimmed their consolidated price target for LifeMD to approximately $9.25 from about $10.63, reflecting reduced revenue growth expectations amid near term competitive pressures in weight management and updated 2025 guidance, partly offset by improved profit margin assumptions and a lower valuation multiple. Analyst Commentary Analysts are broadly recalibrating their LifeMD models in light of softer than expected Q3 results and updated 2025 guidance, with price targets now clustering in the mid single to low double digit range.LFMD: Competitive Pressures Will Drive Market Share Shifts After 2025 Resets
LifeMD’s analyst price target has been reduced from $12.88 to $10.63. This change reflects updated guidance and competitive headwinds that analysts link to recent financial underperformance and increased pressure in the company’s weight management business.Expanding Care Domains And Telemedicine Will Unlock New Markets
Analysts have lowered their price target for LifeMD to $13.25, reflecting ongoing regulatory and partnership risks in the GLP-1 market that offset strong platform growth and market share gains. Analyst Commentary Bullish analysts are optimistic due to LifeMD’s successful scaling of its national, tech-enabled virtual care platform, which covers multiple high-demand healthcare verticals including primary care, weight management, and behavioral health.Positive Sentiment Still Eludes LifeMD, Inc. (NASDAQ:LFMD) Following 46% Share Price Slump
Aug 07LifeMD, Inc. (NASDAQ:LFMD) Soars 37% But It's A Story Of Risk Vs Reward
Jun 21LifeMD, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 09LifeMD, Inc.'s (NASDAQ:LFMD) Shares Leap 50% Yet They're Still Not Telling The Full Story
May 07
New HRT, GLP-1 And Medicare Programs Will Elevate Care
Expansion in Medicare programs and integration with Gifthealth are set to enhance LifeMD's market reach and boost revenue through improved patient retention.LifeMD is a diamond in the making
Telehealth is the future of healthcare in america and around the world. Most people don’t want to wait hours in the hospital or even weeks for an appointment. Telehealth offers those services the sameA Look At The Intrinsic Value Of LifeMD, Inc. (NASDAQ:LFMD)
Mar 31It's Down 27% But LifeMD, Inc. (NASDAQ:LFMD) Could Be Riskier Than It Looks
Mar 08LifeMD: Dilution Ramps Up As Revenue Moves Higher
Feb 01LifeMD, Inc.'s (NASDAQ:LFMD) Intrinsic Value Is Potentially 82% Above Its Share Price
Dec 06LifeMD: A Story I Want A Small Piece Of
Dec 04LifeMD, Inc.'s (NASDAQ:LFMD) Shares Leap 31% Yet They're Still Not Telling The Full Story
Nov 09LifeMD: Are The Commons Too Cheap?
Sep 23LifeMD: Selling WorkSimpli Could Be A Catalyst
Sep 10It's Down 27% But LifeMD, Inc. (NASDAQ:LFMD) Could Be Riskier Than It Looks
Aug 16LifeMD: High Growth GLP-1 Telehealth Play At A Discount
Jul 31LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare
Jun 11LifeMD: Moving Towards Profitability
May 22Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?
Apr 25Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely
Mar 30LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program
Mar 13LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability
Jan 22LifeMD: A GLP-1 Play With A Kicker
Jan 11Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?
Jan 05Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper
Jan 05Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?
Dec 03Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come LifeMD guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 25 | 194 | -15 | 157 | 7 |
| 30 Sep 25 | 250 | -11 | 200 | 11 |
| 30 Jun 25 | 243 | -12 | 198 | 10 |
| 31 Mar 25 | 234 | -14 | 195 | 10 |
| 31 Dec 24 | 155 | -27 | 139 | 7 |
| 30 Sep 24 | 194 | -23 | 175 | 9 |
| 30 Jun 24 | 180 | -25 | 162 | 8 |
| 31 Mar 24 | 164 | -26 | 149 | 7 |
| 31 Dec 23 | 153 | -24 | 137 | 6 |
| 30 Sep 23 | 136 | -32 | 128 | 5 |
| 30 Jun 23 | 129 | -33 | 123 | 4 |
| 31 Mar 23 | 123 | -39 | 125 | 4 |
| 31 Dec 22 | 119 | -49 | 131 | 3 |
| 30 Sep 22 | 118 | -55 | 136 | 2 |
| 30 Jun 22 | 112 | -61 | 137 | 2 |
| 31 Mar 22 | 104 | -64 | 134 | 1 |
| 31 Dec 21 | 93 | -62 | 125 | 1 |
| 30 Sep 21 | 78 | -75 | 131 | 1 |
| 30 Jun 21 | 64 | -85 | 129 | 1 |
| 31 Mar 21 | 51 | -73 | 106 | 1 |
| 31 Dec 20 | 37 | -63 | 85 | 0 |
| 30 Sep 20 | 28 | -32 | 48 | 0 |
| 30 Jun 20 | 20 | -9 | 21 | 0 |
| 31 Mar 20 | 14 | -5 | 14 | 0 |
| 31 Dec 19 | 12 | -3 | 12 | 0 |
| 30 Sep 19 | 11 | -3 | 10 | 0 |
| 30 Jun 19 | 10 | -3 | 10 | 0 |
| 31 Mar 19 | 9 | -3 | 9 | 0 |
| 31 Dec 18 | 8 | -2 | 8 | 0 |
| 30 Sep 18 | 6 | -2 | 7 | 0 |
| 30 Jun 18 | 6 | -2 | 6 | 0 |
| 31 Mar 18 | 5 | -1 | 5 | 0 |
| 31 Dec 17 | 4 | -1 | 4 | 0 |
| 30 Sep 17 | 5 | -2 | 4 | 0 |
| 30 Jun 17 | 3 | -1 | 5 | 0 |
| 31 Mar 17 | 4 | -2 | 5 | 0 |
| 31 Dec 16 | 5 | -1 | 4 | 0 |
| 30 Sep 16 | 5 | -1 | 4 | 0 |
| 30 Jun 16 | 4 | 0 | 2 | 0 |
| 31 Mar 16 | 3 | 0 | 1 | 0 |
| 31 Dec 15 | 1 | 0 | 1 | 0 |
| 30 Sep 15 | 1 | 0 | 1 | 0 |
| 30 Jun 15 | 1 | 0 | 1 | 0 |
Guadagni di qualità: LFMD al momento non è redditizia.
Margine di profitto in crescita: LFMD al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: LFMD non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 34.6% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di LFMD nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: LFMD non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Healthcare Services ( 27.3% ).
Rendimento del capitale proprio
ROE elevato: LFMD ha un Return on Equity negativo ( -44.19% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/04 17:30 |
| Prezzo dell'azione a fine giornata | 2026/05/04 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
LifeMD, Inc. è coperta da 10 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| David Larsen | BTIG |
| Sarah James | Cantor Fitzgerald & Co. |